All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 2, 2021
Home » Blogs » BioWorld MedTech Perspectives » On the Short Regulatory Horizon

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / FDA / National Institutes of Health

On the Short Regulatory Horizon

Sep. 6, 2011
By Mark McCarty
No Comments

 

As the saying goes, there are things we know we don't know, but here are three things we do know, namely guidances that will affect device makers. One of these might have the effect of making some clinical trials less expensive, but another could put the brakes on provider training even in first-in-human studies unless the sponsor is willing to roll out a training protocol for all physician users in the post-market setting.

FDA to put brakes on surgeon training?

FDA issued a mid-August draft guidance for device clinical trials indicating antipathy toward a sponsor's training of doctors in trials unless the sponsor is willing to do the same for doctors in routine practice. This would seem to apply even to studies engaged prior to the pivotal clinical trial.

The draft also reintroduces the boilerplate pertaining to the standard of "least burdensome," which had been omitted from a number of documents issued by the agency over the past 18 months. This guidance defines the phrase as “a successful means of addressing a pre-market issue that involves the most appropriate investment of time, effort and resources on the part of industry and the FDA,” seemingly adding FDA to the bodies subjected to the least burdensome requirements.

NIH updates 1995 financial conflict guidance

The Department of Health and Human Services recently cut in half the threshold for reports on potential financial conflicts of interest (FCOI), but it appears that publicly funded research institutions will not have to post all financial relationships on a website, but make the information available when requested.

The Aug. 23 NIH statement indicates that the new threshold for determining “significant financial interest” will for the most part be reset from $10,000 to $5,000, and a subsequent passage states that before an institution spends any government monies, that institution must “post on a publicly accessible web site information” on significant financial interests “of senior/key personnel” for whom a conflict might be imputed, seemingly eliminating the need to routinely post information online for all clinical researchers at that institute.

FDA draft guidance for risk-based clinical trial monitoring

FDA released a late August draft guidance for clinical trial monitoring that opens the door to less granular monitoring of clinical trials via the "greater use of centralized monitoring methods."

FDA says there is a consensus regarding risk-based monitoring processes that "are more likely to ensure subject protection and overall study quality" by zeroing in on “the most critical data elements,” rather than on "routine visits to all clinical sites" in pursuit of "100% data verification."

Among the features of centralized monitoring cited by FDA is the use of data checks to ensure the completeness of data from case report forms, but the guidance also states that sponsors should consider identifying higher-risk sites for on-site monitoring as well. The draft recommends further that sponsors or CROs use statistical analyses "to identify data trends not easily detected by on-site monitoring."

Several exceptions pertain here, including trials with adaptive designs, trials that call for "multiple device placement," and trials that are not blinded.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 1.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 1.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing